SOUTH SAN FRANCISCO, Calif., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will host an analyst and institutional investor meeting on Thursday, October 4, 2012, from 5:00 to 6:30 PM Eastern Time in New York City. The event will include an overview of vosaroxin and the VALOR trial, a pivotal Phase 3, randomized, controlled, double-blind, multinational clinical trial in first relapsed or refractory acute myeloid leukemia (AML), as well as the Less Intensive 1 (LI-1) Study being conducted by the United Kingdom's National Cancer Research Institute (NCRI) Haematological Oncology Study Group. The event will be moderated by Daniel Swisher, Chief Executive Officer of Sunesis, and will include presentations by, and an in depth panel discussion with, key opinion leaders in AML, including VALOR principal investigators. Presentations will be followed by a question and answer session. The panel will include:
- Alan K. Burnett, MD, Professor of Medicine, Head of Haematology, Department of Medical Genetics, Haematology and Pathology at Cardiff University School of Medicine;
- Eric Feldman, MD, Chair of the VALOR Steering Committee, Professor of Medicine and Director of the Leukemia Program and Hematological Malignancies at Weill Cornell Medical College; and
- Farhad Ravandi, MD, a principal investigator of VALOR, Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
About AMLAML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The American Cancer Society estimates there will be approximately 13,780 new cases of AML and 10,200 deaths from AML in the U.S. in 2012. Additionally, it is estimated that the prevalence of AML across major global markets (U.S., France, Germany, Italy, Spain, United Kingdom, and Japan) is over 50,000. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients. About Sunesis Pharmaceuticals Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com. The Sunesis Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8773 SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
CONTACT: Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717